Archexin offers potential to target and deal with multiple life-threatening cancers.

Archexin offers potential to target and deal with multiple life-threatening cancers, finds new study Rexahn Pharmaceuticals, Inc. AKT1 may promote cell survival and can be consequently implicated in tumor growth in a wide range of cancers. Related StoriesViralytics enters into clinical trial collaboration agreement with MSDNew results reveal association between colorectal tumor and melanoma drug treatmentMeat-rich diet may increase kidney cancer riskThe research to be published in the Journal of Cellular Biochemistry on November 1, 2009 , also found that the mixed treatment of AKT1 AO with cytotoxic medicines showed sustained anti-tumor activity in human renal carcinoma cell range hypothyroidism-in-adults.html .